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Abstract 
Early 4-hydroxyperoxycyclophosphamide (4-HC) 
resistant hematopoietic progenitor cells (pre-
co lony-forming units, pre-CFU) were evaluated by 
a two-step liquid culture system, (earlier pro-
genitors), pre-CFU, as well as by th e convention-
a l semi-solid mixed colony assay (later progeni-
tors) for their growth response to interleukin-6 
(IL-6), int erl eukin-3 (IL-3), and a combination 
of both factors. The effect of the IL-6/IL-3 
combination was compared to that of IL-l/IL-3. 
IL-3 alone proved less effective in supporting 
ea rli er pre-CFU cells than later progenitor 
ce ll s. In a previous work IL-6 promoted the 
growth of early multipotential progenitor cells 
ci rculating in hairy cell leukemia (HCL) 
patients. IL-6 alone did not stimulate growth 
of e ither ear ly or later normal progenitor cells. 
However, a significant synergistic effect was 
obtained when IL-6 and IL-3 were added together 
(p<0.05) . IL-6/IL-3 syner gism was more potent 
than IL-l/IL-3 in promoting growth of colonies. 
The previously described synergis t ic effect of 
IL-1/IL-3 seems to be independent of IL-6. 
Thus, our results suggest that the multi-
f unctional cytokine IL-6, may be of use in 
shortening the engraftment time in bone marrow 
transplantation. 
KEY WORDS: IL-6/IFN- 82; IL-3; Colony forming 
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Introduction 
The formation of mature blood cells comes at 
the end of a process which s tarts by th e prolife-
ration of specifically committed pro genitor cells 
ca lled colony forming units (CFUs). Progenitor 
ce lls as well as mature blood cells are tr ansit 
populations with little capacity of se lf- genera-
tion (2,11). Progenitor cell numbers are main-
tained by th e proliferation of a pre-CFU popula-
tion among th em are ear l y hematopoietic stem 
ce lls. These ce ll s are known to r eside in a non-
cyc ling s ta ge Go (8) but after ent eri ng the cell 
cycle the y pos sess a distinct se lf- genera tion 
capac ity. 
Ear ly human stem cells are dif ficu lt to 
iso late and identify. Ear ly progenitor cell 
population s can be enriched by positive se l ect ion 
with the CD34 (MylO) monoclonal antibody (3), or 
by ne ga tive se lection of all known accessory 
cells and committed progenitors. Some investiga-
tor s use a blast colony assay to assess the early 
pre-CFU population (14). 4-hydroperoxycyclophos-
phamide (4-HC) has a sparing effec t on non-
cyc ling early ste m cells (SJ, and eliminates 
committed progenitors (13). This is supported by 
the observation that 4-HC treated marrow is cap-
ab le of r eco ns tituting normal hematopoiesis 
following autologous bone marrow tran sp lantation 
(21). 4-HC and further enrichment by a two-step 
sys tem, in which pre -CFU cells are "primed" in 
liquid culture for one week, was used in our 
laboratory to s tudy the effe cts of different 
co lony stimulating factors (CSFs) on the pre-CFU 
ce lls. 
Interleukin 3 (IL-3) ha s been shown by many 
investigators to be a multipotential CSF (4,15) 
acting on multipotential progenitors, i . e., CFU-
Mix or CFU-GEMM (colony forming unit granu loc yt e, 
erythroid, macrophage and megakaryocyte), but has 
a lesser effect on pre-CFUs. Other CSFs such as 
GM-CSF (granulocyte/ macroph age CSF) and M-CSF 
(macrophage CSF) act on committed progenitors. 
Hematopoi etin-1 (HP-1), previously termed 
synerg istic factor, induces stem cells to become 
responsive to other CSFs (12). HP-1 acts syner-
gistically with IL-3 in supporting proliferation 
of ea rl y hematopoie tic progenitors (1,25). It is 
now evident that most of the HP-1 activity is due 
to Interleukin-I alpha (IL-1) (17). Recently a 
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combination of Interleukin-6 a l so named Inter-
feron-S-2 and IL-3 proved superior to IL-1 and 
IL-3 in supporting colony formation in 2-day post 
SFU murine bone marrow (BM) cells (9). 
Interleukin 6 also named Interferon Beta 2 
(IL-6/IFN- S2) was first described and cloned 
from dsRNA induced human fibroblasts by its beta 
IFN type an ti-viral and anti-growth activity (22, 
27). IFN- S2/IL-6 was found to be identical with 
B-cell stimulating factor (BSF-2) and also with 
hepatocyte stimulating factor (HSF) (20) . This 
multifunctional cytokine is produced in a regula-
ted fashion by a varie t y of normal cells (e.g., 
fibroblas t s, endothe lial cells and monocytes). 
The name IL-6 will be used in this work. 
IL-1, tumor necrosis factor (TNF), platelet 
derived growth factor (PDGF) and other cytokines 
tri gger expression of IL-6 in fibroblasts (23). 
Thus, the possibility of an indirect hemato-
poietic effect of IL-1 via IL-6 on stem cells 
was also evaluated in the present work. 
Earlier s tudi es in our l aboratory showed 
that IL-6 was active on a special progenitor 
ce ll with multipotential capability: lympho-GEMM 
(LGEMM), found in peripheral blood (PB) from 
pa tients with Hairy Cell Leukemia (HCL) (16,20). 
These cells may represent earlier cells than the 
CFU-Mix. The present work further demonstrates 
that IL-6 also acts on normal ear l y hematopoietic 
progenitors. 
Materials and Methods 
Bone Marrow Sampl es 
Normal human bone marrow (BM) was obtained 
with informed consent (according to the guide-
lines of the Helsinki Committee) from adults in 
whom the bone marrow was not involved with any 
pathology. 
Peripheral Blood Samples 
PB sampl es were obtained from healthy adult 
laboratory workers and also from HCL patients. 
Cell Separa tion Procedure 
BM and PB aspirated into preservative free 
heparin were separa ted over a Fico ll-H ypaque 
gradient (Pharmacia) at 400g for 30 min and the 
interface mononuclear cells collected, washed 3 
times and resuspended in Iscove's Modified Dul-
becco's Medium (IMDM). T-cell depletion was 
performed using AET treated sheep red blood cells 
fo llowed by a second centrifugation on a Ficoll-
Hypaque gradient. The T-depleted fraction was 
then depleted of macropha ges by adherence to 
pla stic at 370c overnight in IMDM with 15% fetal 
calf serum (FCS). Preparation purity was over 
90%. 
4-hydroperoxycyclophosphamide (4-HC) treatment 
To enrich for early human progenitors, low 
density non-adherent, non-rosetting BM and PB 
ce ll s were tr eated with 4-HC. Briefly, th e mono-
nuclear cells were incubated with 4-HC at lOOµg/ 
ml (as determined by a dose response curve) for 
45 min at 370c with frequent agitations and 
washed three times with cold IMDM. 
Colony Assays 
Day-0 cultures: 105 cells were plated in 1ml 
of IMDM containing 0.9% methylcellulose, 5xl0 5 
mg/ml 2-mercaptoethanol, 10% FCS, 20% fresh 
frozen plasma and when indic a ted 7.5% vol/vol 
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PHA-LCM (phytohemagglutinin l eukocy t e condi tioned 
medium). Al l plates contained 1 U/ml recombina nt 
ery thropoietin (Connaug ht, Ontario, Canada). The 
cultures were incubated in a fu lly humidi:ied 
atmosphere containi ng 5% CO2 at 37°c for :4-16 
days. When recombinant growth fac tor s were added 
to the cultures no PHA-LCM was included. 
Liquid Culture: The ce ll s used in th :s two-
step system (10) were tr eated as above with 4-HC, 
resuspended at 105 cells/ml in IMDM conta i ning 
10% FCS, different growth factors and incubated 
for 5 to 7 days. Control cultures with PHA-LCM 
as a pool of growth factors were inc lud e,d. At 
the end of the incubation period , the eels were 
pelleted and plated in the methylcellulos e assay 
as in day-0 cultures, with PHA-LCM as a source of 
CSFs. The increase in th e number of secondary 
colonies reflects the expansion of early progeni-
tors in response to the primary stimulus during 
the liquid phase. 
Definition of Colon y Types 
Coloni es were classified according to their 
appeara nce, using an inverted microscope, (Nikon, 
Diaphot) as: CFU-Mix (colony forming units gra nu-
locyte, erythroid, macrophage and megakar yocytic) 
CFU-GM (colony forming units granulocyte/macro -
phage), BFU-E (burst forming units erythroid). 
The identity of cel l s within colonies is rou tin e-
ly checked by picking out colonies, spreading on 
slides and staining with Giemsa. 
llematopoietic Factors _ 
Recombinant IL-6 (rIL-6) was supplied by 
M. Revel and M. Rubinstein (Interpharm Nes-Ziona, 
Israel). rIL-6 from mammalian ce ll s was produced 
in Chinese Hamster ovary cells (CHO) clones (28). 
Bacteria l rIL-6 was produced in E.coli (7). 
rTL-6 was use d at concentrations 0.3 to 30 U/ml. 
Recombinant Interleukin-3 (rIL-3) was used 
at 10 U/ml. 
Recombinant Interleukin-I (rIL-1) was used 
at 2 U/ml. 
Monoclona l anti-IL-6 antibodies from hybridoma 
clone 34 were supplied from A. Zilberstein 
(Weizmann Inst.). Dilutions of 1:100 to 1:500 in 
IMDM were used in the experiments. 
Statistical Analysis 
Mean and Standard error of mean (SEM) for 
colo nies grown in duplicate dishes were assessed 
and sets of data compared usin g th e Wilcoxon's 
Rank test for unpaired samples. 
Results 
Effect of rIL-6 on hematopoietic co lon y forma-
tion in HCL-PB: 
During our studies on the growt h of hemato-
poietic colonies from peripheral blood (PB) of 
HCL leukemi a patients (16), we observed that the 
addi tion of IFN-alpha or beta-1 species produced 
a s li ght but consis tent stimu lation in con trast 
with the marked inhibition see n on normal hema-
topoietic progeni tors. The addition of rIL-6 
(CHO) to PHA-LCM when compared to IFN-alpha, 
pro duced a much l arger stimulation of colony 
gro wth in HCL-PB (not shown). rIL-6 alone also 
st imulated growth of progenitor cells in HCL-PB 
as shown in fig. 1. A dose response curve of 
colony formation in HCL PB was performed. The 
IL-6 and IL - 3 synergism 

















0 LCM IL6 
Figure 1. Effect of rIL-6 (CHO) 0.3 U/ml on PB 
progenitor cells from HCL patients in liquid 
culture s . Results are mean of 6 independent 
expe riments in duplicates. (SD less than 10%). 
optimal concentrations were 0.03 to 30 U/ml of 
recombinant IL-6 (fig.2). In our experiments we 
used 0.3 U/ml (anti-viral U/ml). 
Ef fect of rIL-6 on normal BM hematopoietic 
colony formation 
Monocyte and T-depleted 4-HC treated normal 
bone marrow cells grown in the day-0 culture 
assay with addition of rIL-6 (CHO), showed no 
sign ificant increase in CFU-GM, BFU-E and CFU-
Mix. These results greatly differed from the 5 
fo ld stimulation in colony growth produced by 
rIL-3 alone (fig.3). rIL-6 (CHO) when added to 
rIL-3 however, promoted a slight increase as 
compared to rIL-3 alone (20 % increase of all 
colony types). These cu l tures were grown without 
PHA-LCM. 
We next compared the combination rIL-6 (CHO) 
and rIL-3 on earlier progenitor cells in the 
liquid two step assay. rIL-3 alone was much less 
effective than in the day-0 cultures. The in-
cre ase in colony formation with rIL - 3 was only 
slightly greater than rIL - 6 alone (fig. 3) . rIL-3 
in day - 0 cultures replaced PHA-LCM complete l y, 
but had a much less prominent effect on the 
earlier quiescent pre-CFU cells. When the pre-
CFU cells .were incubated with rIL-3 and rIL-6 
(CHO), a clear synergism was demonstrated (fig. 
3). When ana l yzing different progenitor cell 
types, a major increase in CFU-GM was evident in 
day-0 cultures whi l e in the liquid assay an 
increase occurred mainly in BFU-E and CFU-Mix 
(fig.4 ) . It is possible that the cycling pro-
geni t ors namely CFU-GM were no l onger avai l able 
in th e liquid assay and therefore rIL-6/rIL-3 
cou l d not infl uence t heir prolifera t ion . 
iIL-6 produced i n E.co l i in duce d simi l ar 
ef fects to CHO (fig.5) . When added a l one , no 
s t imul ation of colony growth was obt ained in day-
0 cu lt ures (left col umns, fig.5) whi l e a slig ht 
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Figure 2. Dose response curve of rIL-6 (CHO) on 
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Figure 3. Compari son between day-0 (lef t co l umns 
co l umns) and l i quid cul tures (rig ht co l umns) 
using r I L- 6 (CHO) 0.3 U/ml. 105 dep l e t ed 4-HC 
trea t ed ce l ls per ml of culture p l ated. Resu lt s 
are mean ±SEM of 5 experiments i n dup l icates and 
are expressed as increase percen t in re l at ion t o 
IL-3 response, considered as 100%. 
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Figure 4. Different colonies (CFU-GM, BFU-E and CFU-Mix) obtained with rIL-6 (CHO), rIL-3 and rIL-6/ 
rIL-3 combination, evaluated in day-0 cultures and liquid cultures. 105 depleted 4-HC treated BM cells 
per ml of culture. Results are mean of 5 experiments in duplicates. rIL-6 (CHO) 0.3 U/ml; rIL-3, 
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D Day-0 cultures 
c:;J Liquid cultures 
Figure 5 . Compar iso n bet ween day-0 and l iq uid 
cul t ures us in g r I L- 6 (E.Co l i) 3 U/ml. Resu lt s 
are mean ±SEM of 7 exper iments in dup l ica t es and 
are expressed as i ncrease percen t in re l at ion t o 
IL-3 respo nse conside r ed 100%. Significan t 
synerg i sm bet ween rIL-6/ rI L-3 as compa r ed t o 
rIL-3 (p<0.05). 
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liquid cultures (right columns, fig. 5). A sig -
nificant synergism was obtained when both rIL-3 
and rIL-6 were added togeth er in the two assays 
as shown in fig. 5 (p<0 . 05). The number of all 
colonies increased in day-0 cultures with the 
combination of rIL-6 and rIL-3 (fig . 6) . In the 
liquid cultures a pronounced increase was see n in 
CFU-Mix, a small effect in BFU-E and almost none 
in CFU-GM (fi g.6) , i.e., rIL-3 alone promoted 
growth of 15 CFU-Mix colonies as compared to 35 
CFU-Mix with rIL-6/rIL-3 (fig . 6). The results 
shown in figures 3 and 5 re l at e t o th e number of 
colonies obtained with rIL-3 and are expressed as 
100%. The calculations of percent increase are 
derived from the number of colonies scored, shown 
in figs. 4 and 6,respectively. 
rIL - 1 when added alone to the cultures be-
haved si mila rl y to rI L-6 and did not pro mote 
growth of colonies. However, synergism betwee n 
rIL-1 and rIL-3 was observed (fig . 5). In exper i-
ments comparing t he combination rIL - 1/rIL-3 vers us 
rIL-6/rIL - 3, the former combination proved l ess 
effec t ive i n s t i mul at i ng growt h (f i g.5). To check 
wheth er rI L-1/r I L-3 synergism is due t o prod uction 
of IL - 6 by some re mai nin g accesso r y ce ll s we use d 
anti-IL-6 monoclona l ant ibodies. The additio n of 
anti -I L-6 antibodies did not a lt er th e synergis m 
and no additive effec t s were obt ai ned with r IL - 1 
and rI L-6, sugges t ing t ha t t he two cyt okines ac t 
each on i t s own (da t a not sho wn). 
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Figure 6. Different colonies (CFU-GM, BFU-E and CFU-Mix) obtained with rIL-6 (E.Coli), rIL-3 and a 
combination of both in day-0 cultures (left) and liquid cultures (right). 105 depleted 4-HC treated BM 
cells per ml of culture. Results are mean of 7 experiments in duplicates. rIL-3, 10 U/ml rlL-6, 3 U/ml. 
Discussion 
The results of our study show that rIL-6 
plays a role in "priming" early progenitor cells 
to respond to rIL-3. To study pre-CFU cell res-
ponses, T and monocyte depleted bone marrow cells 
after 4-HC treatment were "primed" in the liquid 
two step culture assay with hematopoietic factors 
including rIL-6, and then checked for growth 
response in methylcellulose assays. Using this 
model, we show that rlL-6 by itself does not 
support colony formation indicating that it does 
not act by itself as a growth promoting CSF. Only 
when both rlL-6 and rIL-3 are present a clear 
synergism can be demonstrated. Different types 
of progenitor cells were stimulated to grow by 
the rIL-6 and rIL-3 combination. In the two step 
system, using either CHO or E.Coli rIL-6, mainly 
BFU-E and CFU-Mix colonies proliferated while in 
the day - 0 cultures CFU-GM predominated (fig .6). 
This variability in cell type response has not 
been described previously, and may suggest two 
different hematopoietic effects of rIL-6 : A 
priming effect on pre-CFU cells and a differen-
tiating effect on granulocyte/macrophage lineage. 
rIL-6 has also been shown to be capable of in-
ducing differentiation of leukemic mouse cells 
(24) and increase of receptors for IL-3 and GM-
CSF has been reported for IL-6/IFN- $2/MG12 on 
leukemic cells (19,24). The lack of effect on 
CFU-GM may also be due to the fact that these are 
later progenitors and maybe eliminated by 4-HC in 
the 5 days cultures, therefore not responding to 
rIL-6. 
Interleukin 1 is another cytokine capable of 
priming pre-CFU cells to respond to rIL-3 (18). 
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We have confirmed the rIL-1/rIL-3 synergism and 
found that rIL-6/rIL-3 is a more active combina-
tion. Both rIL-1 and rIL-6 are multifunctional 
cytokines involved in the immune response and 
other important biological processes. Induction 
of IL-1 by IL-6 accounting for the pre-CFU cells 
response seems improbable since addition of mono-
clonal antibodies to IL-6 did not abolish the 
IL-1/IL-3 effect and no additive growth responses 
were obtained when both rIL-1 and rIL - 6 were used 
together . 
It is not yet clear whether IL-6 acts 
directly on the stem cells . To answer this ques-
tion, higher purity of target cells i.e . , CD34 
MylO positive cells and the 4-HC two step assay 
are needed. Possible influence of T accessory 
cells known to be activated by IL-6 (26), or 
influence of other factors produced by stromal 
elements in the microenvironment also remain to 
be eva luated . In any case, the synergistic 
effect obtained with rlL-6 and rIL-3 suggests 
that this combination may be useful in fastening 
reconstitution of hematopoiesis in bone marrow 
transplantation. The IL-6/IL-3 synergism may 
prove equal or superior to other combinations 
already tried in vivo (6). 
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Discussion with Reviewers 
H. Gaml iel: The present study used li ght micro -
scopy and cytoc hemical stains to identify 
colonies. Indeed, it appears that light micro-
scopy might suffice to dis tin guish between Mix, 
GM and BFU-E colonies . Would you agree that 
e l ectron microscopy in conjunction with immuno-
lab elin g may enable even better iden ti fication of 
co l onies and sub - colonies, e .g., G and M sub-
co l onies etc.? Also, why l ymphocytes are not 
represented in any of th e above colonies ? Should 
not they be part of the CFU-Mix colonies? 
Authors: Electron microscopy with immuno-
labeling would be of great help in identifying 
lymphocyt es . It may be too cumbersome for a 
routin e work or big number of exper iment s but in 
the context of a pertinent research it would 
definitive l y add in characterization of lympho-
cy te s . There are no l ymphocytes (by morphology) 
that grow in mixed co l onies (CFU-Mix) from normal 
blood or bone marrow and the reason for it is not 
ye t enti rely clear. Some attribute it to th e age 
of progenitor cells that are a l lowed to gro w 
under the given cu ltur e conditions but it may 
a lso be that so me factors are lackin g that 
promote l ymphocytic diff ere ntiation. Lymphocytes 
deriv ed from a common lymphomyel oid progenitor 
have been described in stem cell diseases and, 
recently by us, in hairy cel l leuk emia (ref 16). 
H. Gamliel: Could you comment on what actua ll y 
trigger s ear l y hemat opoietic stem ce lls to ent er 
the ce ll cycle, mainl y , if priming pre -CFU ce ll s, 
as presently reported, also leads to changes in 
the self generation capacity of th ese cells, 
besides turning th e cells responsive to ot her 
gr owth factors? 
Autho rs: Early hematopoietic s t em ce ll s are 
qui escent ce ll s (Go phase) and there is l ack 
of knowledge as to what triggers them to enter 
the cell cycle. I t seems that IL-6 may be 
capab l e of doin g this by promoting the cells to 
respond to IL- 3. Other candidates would be G-
CSF and IL-1. This que s tion is crucial and I 
be l ieve that th e answer wi ll be possible when 
true stem cel l s are isolated and fu ll y charac-
terized. 
H. Gamli e l: What are the ac tu a l numbers of pre-
CFU ce ll s that are left af t er tr eat in g a bone 
marrow aspirate? If for exampl e you s tart with 
10x10 6 mononuclear ce ll s, how many pre-CFU cells 
can be harvested from such a sample? 
Authors: The liquid culture assay used for 
pre-CFU cells is a modification of the 
Johnson and Bradley t ype of assay for s t em ce ll s 
in the mouse. It i s based on th e conc ept of a 
qui escen t s t at e of s t em ce lls and sho uld a llow 
enric hment for earl i er non-cycling ce ll s. The 
numbers of pre-CFU cells that are left after 
treating a bone marrow aspi rat e when exposed to 
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IL-6 IL-3 are of a magni tude of approxima t e l y 
1:1000. This can be augmented by thor ough l y 
dep l eted sa mples with a panne l of monoclon a l 
ant ibodies specific for l ineage depe ndent cel l s 
and treatment with 4-HC or 5~U, that kill cyclin 
cycling ce ll s and spare engraftin g hematopoietic 
progeni t or cells. 
H. Gamli el : Could you briefly review r eports on 
s t em cells in th e peripheral blood of leukemic 
patients, mainly, in hairy ce ll l eukemia (HCL). 
Is it possible to positive l y iden ti fy such cells 
in blood sampl es from HCL just by immunolabeling 
them, e.g., for CD34? In cases of HCL, are th e 
circu l at ing progenitor cells different from the 
progenitor cel l s common to the B-cel l and mono-
cy t ic lineages? 
Authors: The presence of lymphomyeloid stem 
cel l s with high self renewa l and lymphoid 
differentiative capability in HCL was described 
by us in 1987 (16). We then showed that these 
primitive precursors bear th e CD34 antigen 
(Leukemia Researc h, in press). Not all CD34 
positive ce ll s however are stem ce ll s but rather 
consist of a frequency of 1 :100, 1:50 at the best 
conditions . We do not know yet if these s tem 
ce ll s are normal s t em ce ll s circu l ating in the 
blood of HCL patients as a response to the fibro-
sis and leukemic process in th e marrow, or if 
those are early cells that underwent a matura-
tional arrest causing accumulation of prep l as -
matic B ce ll s (hairy cells) . A chromosoma l or 
enzymati c marker would help clarify thi s impor-
tant issue of cause or consequence. The cells 
common to Band monocytic linea ges ar e not the 
sa me as the circulating pro ge nitor ce ll s in HCL. 
Little is known in man abou t characteriza tion of 
the l ymphoid - stem ce ll arm in hematopoietic 
development. 
P.M. Grimley: How many different blood sampl es 
were examined to determine th e s tatistic al 
va lidit y of IL-3/IL-6 synergi sm? Whil e th e 
Wil coxon rank t es t is usefu l, da t a fro m just one 
sa mple woul d not nece ssari l y indicate biolo gic 
consistency. 
Autho rs: Five different marrow samples were 
examined to determine th e IL-3/IL-6 synergism. 
This is s tat ed in th e l ege nd for fig. 3. 
P.M. Griml ey: Have ther e been any ce ll cycle 
ana l ysis of pre -CFU cells af t er one week in the 
li quid medium? Are such result s consistent 
amongst sampl es fro m different individuals? Since 
marrow pro l iferative ac ti vity gra dually declines 
with age, was thi s a factor with differen t 
donors? Do the colonies obtained from day-0 
cultures and af t er pr iming di ffer sta ti stica ll y 
in ce ll cyc l e distributions, af t er for exa mple 
IL-3 + IL - 6 .tre atment shown in fig. 3? 
Authors : We have not analysed cell cycl e. It 
is however known that earlier stem cells are 
quiesc en t (in Go). In th e Ogawa publication 
(t ex t, ref. 15) cited in references ther e are 
s ome evidences suggestin g that IL-6 may shor-
ten the time in Go th erefore enabling cells 
to respond to IL-3. It may be true that 
older donors may have l ess colony growth . We 
Michalevicz R., Lifshitz D., Revel M. 
have not examined thoroughly this question 
and thus cannot comment further on this point. 
P.M. Grimley: I cannot find the data which 
supports your statement that IL-3 is much less 
effective in supporting pre-CFU cells assayed by 
the two-step liquid culture system. This is not 
apparent, for example in fig. 3. 
Authors: You are entirely right. Our 
statement is not apparent if one looks only at 
fig. 3 where we choose to show the effects of 
rIL-6 and synergism between rIL-6 and rIL-3 as 
related to the rIL-3 activity. Therefore, the 
results of both day-0 and liquid cultures are 
shown as related to growth with rIL-3 (considered 
100%). The differences are evident if one looks 
at the data showing actual colony numbers in 
figs. 4 and 6. IL-3 indeed was a less stronger 
inducer of colony growth in the pre-CFU assay as 
compared to its stimulatory effect on day-0 
cultures on CFU-Mix. This is in accordance with 
the findings of most groups working on stern 
cells. IL-3 is a very potent stimulator of 
growth at relatively early stages of hernatQ-
poietic precursors but probably not on the 
earliest pre-CFU cells. The common adopted view 
of most workers in this field is that IL-3 is 
not the "stern cell factor" and its response is 
mainly on cells that were first primed and pre-
pared to respond to IL-3 by earlier factors. 
Among these are IL-6 and IL-1 as well as G-CSF. 
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